2018-01-24 14:28:47 UTC

Headlines from the 2018 Gastrointestinal Cancers Symposium

Jan. 24, 2018

Novel approaches for CRC screening, new treatment options for GI cancers, and more presented at the meeting, which is co-sponsored by AGA.

The 2018 Gastrointestinal Cancers Symposium took place Jan. 18-20, 2018, in San Francisco, California. During the meeting, investigators presented groundbreaking research designed to improve the diagnosis and treatment of GI cancers. Here are some of the most noteworthy headlines from the 2018 meeting.

Promising Results Using Liquid Biopsy to Improve CRC Early Detection
Researchers in Taiwan developed a screening test for early colorectal cancer (CRC) detection that requires a simple blood draw to assess for circulating tumor cells in the blood. The test demonstrates 88 percent accuracy to detect all stages of colorectal illness, including precancerous lesions. If validated and made commercially available, this test could be readily integrated into a patient’s routine physical exam, thereby increasing CRC screening compliance.

CELESTIAL Results May Lead to Cabozantinib Approval in Second-Line HCC
The phase III CELESTIAL trial met its primary endpoint by demonstrating a survival advantage with cabozantinib in patients with advanced hepatocellular carcinoma (HCC) that progressed following prior systemic therapy. Other outcomes included improvements in progression-free survival and objective response rate, as well as an acceptable safety profile, thus positioning cabozantinib for potential approval in the second-line setting in HCC.

RAINFALL Meets Primary Endpoint, But Ramucirumab Will Not Be Pursued for a First-Line Indication in G-GEJ Cancer
Results of the global, randomized, double-blind, placebo-controlled, phase III RAINFALL trial established the statistical benefit of ramucirumab, a monoclonal antibody targeting VEGFR-2, added to standard chemotherapy for patients with previously untreated metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma. The findings revealed a significant 25 percent reduction in the risk of disease progression or death for the primary endpoint of progression-free survival (PFS). However, the reduction corresponded to only a nine-day improvement in median PFS, so the clinical benefit of frontline ramucirumab is debatable.

The Gastrointestinal Cancers Symposium is co-sponsored by AGA, the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Surgical Oncology (SSO).

More news from the 2018 Gastrointestinal Cancers Symposium is available at https://gicasym.org/daily-news.

More on Cancer of the Gallbladder and Bile Ducts

Digestive Disease Week® (DDW)

Dec. 19, 2017

Digestive Disease Week® (DDW) is the premier meeting for the GI professional. Every year it attracts approximately 15,000 physicians, researchers and academics from around the world who desire to stay up-to-date in the field.

Hand-Picked Gastrointestional Oncology Sessions at DDW® 2017

April 10, 2017

Rhonda Souza, MD, AGAF, (chair) and John P. Lynch, MD, PhD, (vice chair) reveal their section's most anticipated DDW sessions.

Trending in AGA Community: Hard Cancer Questions

Aug. 3, 2016

AGA Community reached 1,000 discussion posts over the weekend. Trending this week in the forum is the topic of cancer risk and prevention.